Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ALK-positive lung cancer trial results show unprecedented progression-free survival.

2.

The way that miR-377 inhibits cells that cause prostate cancer.

3.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

4.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

5.

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot